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Inflammation of actinic
keratoses after docetaxel
Inflammation des kératoses actiniques sous
docétaxel
The occurrence of local inflammation at the side of actinic
keratosis (AK) after systemic chemotherapy is not frequently
reported [1]. It has mainly been described with 5-fluorouracil.
We report on a case that occurred after docetaxel alone.
Observation
An 81 year-old man with advanced hormone-refractory prostate
cancer was referred for an acute cutaneous eruption of the face
and upper part of the body after initiation of docetaxel biweekly.
In 2001, the patient was diagnosed with prostate adenocarci-
noma (stage T2b, Gleason score 7) submitted to prostatectomy.
He was then treated by bicalutamide and leuprorelin acetate. In
May 2017, he was found metastatic lesions in the kidney and
bones and initiated biweekly docetaxel 50 mg/m2 with dexa-
methasone as premedication 7,5 mg as priorly reported [2] in
association with denosumab. A rash appeared rapidly after the
first docetaxel infusion with erythematous scaly lesions on the
upper part of the body, the face and the upper trunk. Symptoms
worsened after every session, so that after the 6th cycle, he was
seen for diagnosis and management. At presentation, the
patient presented with round and oval, 1 to 2 centimeters,
macula and patches distributed on the forehead, cheeks, and
nose (figure 1A) but also the upper trunk (figure 1B), shoulders
and upper back (figure 1C). The lesions were asymptomatic,
neither itchy, or painful, slightly scaly and rough to the touch.
The underlying affected skin featured clear signs of chronic sun
exposure (helioderma). The scalp was devoid of any lesion. The
clinical presentation was evocative of inflamed AK. Differential
diagnosis at consultation included subacute cutaneous lupus.
The patient did not recall any skin lesions prior to this eruption.
Physical examination was otherwise unremarkable. A 3-mm
punch skin biopsy of a lesion of the upper back was performed
and confirmed the diagnosis of AK (figure 2). Highly potent
(betamethasone) and mild (desonide) corticosteroid ointments
were applied on the trunk and the face respectively while
docetaxel was maintained. At one month follow-up, the condi-
tion improved but without complete clearance. He developed
nail onycholysis. The patient responded well to the chemother-
apy with an improvement of the metastatic lesions and a drop of
PSA levels but docetaxel had to be stopped because of the
accumulation of side effects such as alopecia, onycholysis,
edema of the lower limbs and peripheral neuropathy.
Discussion
The inflammation of AK from systemic chemotherapy is a long
time known phenomenon [3], albeit not frequently reported
Figure 1
A. Erythematous scaly eruption consistent with inflamed actinic
keratoses of the face. B. Upper trunk. C. Upper back
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[1]. It has mainly been described with 5-fluorouracil or its
prodrug (capecitabine) [4,5]. Other systemic drugs (cisplatin,
dactinomycin, doxorubicin, vincristine, pemetrexed [6], bend-
amustine [7]) have been involved, even though in case of
polychimiotherapy, it can be challenging to assess which drug
is the culprit. To our knowledge, docetaxel has been reported
only on one prior occasion [8]. However, in this case, docetaxel
was administrated with carboplatin. Inflammation of AK has
been observed with targeted therapies such as sorafenib [9],
erlotinib [10], and panitumumab [11]. As noted by Johnson et al.
[1] and as illustrated in our case, AK are usually not clinically
apparent before chemotherapy. The physiopathogeny of this
local inflammation relies on the DNA synthesis abnormalities
that characterize any AK [12]. Thus, they are more like to react to
chemotherapy. However, not every patient, nor all chemothera-
pies are responsible for such reaction. 5-FU is the most fre-
quently responsible and as a matter of fact topical 5-FU is still
used in dermatology in the management of local AK [12]. It is
not known whether such reaction can be seen as a favourable
prognosis factor.
To the best of our knowledge, we report the first case of
inflamed AK after docetaxel alone. The occurrence of inflamed
AK is not an indicator of any drug allergy and should not be an
indication for chemotherapy withdrawal.
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Figure 2
Biopsy specimen of the upper back showing showing
parakeratosis, dyskeratotic keratinocytes with increased mitoses
and solar elastosis in the dermis (hematoxylin-eosin,  400)
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